Literature DB >> 17533584

Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet.

J Aberle1, I Fedderwitz, N Klages, E George, F U Beil.   

Abstract

The endocannabinoid system (ECS) plays an important and not yet fully understood role in hypothalamic and peripheral regulation of food intake, obesity, and metabolism. Two frequent single nucleotide polymorphisms (snp) have been identified in members of the ECS: the 1359 G/A variant in the cannabinoid receptor 1 ( CB1) and the P129T polymorphism in fatty acid amide hydrolase ( FAAH), a key degradation enzyme of endocannabinoids. -While for the 1359 G/A variant an association has been shown only with psychiatric diseases such as drug-abusing schizophrenia, the P129T polymorphism has recently been proved to be correlated to a higher body mass index (BMI) in a group of black and white Americans. However, no knowledge exists as to whether these variants affect the outcome of a low fat diet in obese subjects. Therefore, we genotyped a group of 451 obese and dyslipidaemic participants and observed the biometric and metabolic outcome of a 6 week low fat diet. While no significance was seen for the 1359 G/A variant, carriers of the P129T mutation in FAAH had a significantly greater decrease in triglycerides and total cholesterol as compared to wild type. The reason for our findings remains to be elucidated, however, a hepatic downregulation of endocannabinoid tone may contribute to the observed outcome in studied subjects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17533584     DOI: 10.1055/s-2007-977694

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  11 in total

Review 1.  Enzymatic pathways that regulate endocannabinoid signaling in the nervous system.

Authors:  Kay Ahn; Michele K McKinney; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2008-04-23       Impact factor: 60.622

2.  Effects of C358A polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) on weight loss, adipocytokines levels, and insulin resistance after a high polyunsaturated fat diet in obese patients.

Authors:  D A de Luis; O Izaola; R Aller; B de La Fuente; D Pacheco
Journal:  J Endocrinol Invest       Date:  2013-12       Impact factor: 4.256

3.  Racial and sex differences in the polymorphisms of the endocannabinoid receptor genes in obesity.

Authors:  Tina K Thethi; Aster Sigel; Shanker Japa; Bonnie Katalenich; Shuqian Liu; Tuyen Nguyen; Joshua Larrazolo; Stephanie Syu; Esther Carefoot; Roberta McDuffie; Vivian Fonseca
Journal:  J Diabetes Complications       Date:  2020-07-17       Impact factor: 2.852

4.  Obesity-related dyslipidemia associated with FAAH, independent of insulin response, in multigenerational families of Northern European descent.

Authors:  Yi Zhang; Gabriele E Sonnenberg; Tesfaye Mersha Baye; Jack Littrell; Jennifer Gunnell; Ann DeLaForest; Erin MacKinney; Cecilia J Hillard; Ahmed H Kissebah; Michael Olivier; Russell A Wilke
Journal:  Pharmacogenomics       Date:  2009-12       Impact factor: 2.533

Review 5.  Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.

Authors:  V Kiran Vemuri; David R Janero; Alexandros Makriyannis
Journal:  Physiol Behav       Date:  2007-11-21

6.  Distinct and replicable genetic risk factors for acute respiratory distress syndrome of pulmonary or extrapulmonary origin.

Authors:  Paula Tejera; Nuala J Meyer; Feng Chen; Rui Feng; Yang Zhao; D Shane O'Mahony; Lin Li; Chau-Chyun Sheu; Rihong Zhai; Zhaoxi Wang; Li Su; Ed Bajwa; Amy M Ahasic; Peter F Clardy; Michelle N Gong; Angela J Frank; Paul N Lanken; B Taylor Thompson; Jason D Christie; Mark M Wurfel; Grant E O'Keefe; David C Christiani
Journal:  J Med Genet       Date:  2012-10-09       Impact factor: 6.318

Review 7.  Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity.

Authors:  David R Janero; Alexandros Makriyannis
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

8.  Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index.

Authors:  Tes M Baye; Yi Zhang; Edward Smith; Cecilia J Hillard; Jennifer Gunnell; Joel Myklebust; Roland James; Ahmed H Kissebah; Michael Olivier; Russell A Wilke
Journal:  Pharmacogenomics       Date:  2008-11       Impact factor: 2.533

9.  A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia.

Authors:  Arun K Tiwari; Clement C Zai; Olga Likhodi; Annika Lisker; Deepika Singh; Renan P Souza; Poonam Batra; Syed H E Zaidi; Sheng Chen; Fang Liu; Imke Puls; Herbert Y Meltzer; Jeffrey A Lieberman; James L Kennedy; Daniel J Müller
Journal:  Neuropsychopharmacology       Date:  2010-01-27       Impact factor: 7.853

10.  Circulating Endocannabinoids and the Polymorphism 385C>A in Fatty Acid Amide Hydrolase (FAAH) Gene May Identify the Obesity Phenotype Related to Cardiometabolic Risk: A Study Conducted in a Brazilian Population of Complex Interethnic Admixture.

Authors:  Cyro José de Moraes Martins; Virginia Genelhu; Marcia Mattos Gonçalves Pimentel; Bruno Miguel Jorge Celoria; Rogerio Fabris Mangia; Teresa Aveta; Cristoforo Silvestri; Vincenzo Di Marzo; Emilio Antonio Francischetti
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.